[
  {
    "title": "BostonGene Announces Collaboration with Ottimo Pharma to Optimize and Accelerate Development of First-in-Class PD-1/VEGFR2 Immuno-Oncology Therapy Using AI",
    "link": "https://www.eagletribune.com/region/bostongene-announces-collaboration-with-ottimo-pharma-to-optimize-and-accelerate-development-of-first-in-class/article_2044b33a-4b63-52bd-8651-b2eff456328e.html",
    "description": "WALTHAM, Mass.--(BUSINESS WIRE)--Jan 8, 2026--",
    "source_id": "eagletribune",
    "pubDate": "2026-01-08 12:56:48"
  },
  {
    "title": "Okta and YourStory to host exclusive webinar on securing the future of autonomous AI agents",
    "link": "https://yourstory.com/2026/01/okta-yourstory-host-exclusive-webinar-securing-future-autonomous-ai-agents",
    "description": "Join Okta executives to discover how Auth0's helps engineering teams ship secure features faster while reducing the total cost of ownership.",
    "source_id": "yourstory",
    "pubDate": "2026-01-08 12:56:18"
  },
  {
    "title": "Jacobs to lead construction of Hut 8\u2019s $7 billion AI data center",
    "link": "https://au.investing.com/news/company-news/jacobs-to-lead-construction-of-hut-8s-7-billion-ai-data-center-93CH-4197191",
    "description": null,
    "source_id": "investing_au",
    "pubDate": "2026-01-08 12:56:10"
  },
  {
    "title": "Jacobs to lead construction of Hut 8\u2019s $7 billion AI data center",
    "link": "https://in.investing.com/news/company-news/jacobs-to-lead-construction-of-hut-8s-7-billion-ai-data-center-93CH-5178487",
    "description": null,
    "source_id": "investing_in",
    "pubDate": "2026-01-08 12:56:09"
  },
  {
    "title": "BostonGene Announces Collaboration with Ottimo Pharma to Optimize and Accelerate Development of First-in-Class PD-1/VEGFR2 Immuno-Oncology Therapy Using AI",
    "link": "https://www.businesswire.com/news/home/20260108720749/en/BostonGene-Announces-Collaboration-with-Ottimo-Pharma-to-Optimize-and-Accelerate-Development-of-First-in-Class-PD-1VEGFR2-Immuno-Oncology-Therapy-Using-AI",
    "description": "WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo Pharma Limited (\u201cOttimo\u201d), an innovative, clinical-stage biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer. The partnership will utilize BostonGene\u2019s advanced artificial intelligence (AI) platform to apply multiomic analytics and expedite th",
    "source_id": "businesswire",
    "pubDate": "2026-01-08 12:56:00"
  }
]